Introduction
Colorectal cancer is one of the most prevalent cancers in the world and despite improvements in surgical technique, many patients die of metastatic liver disease every year. Therefore, the effective treatment of liver metastases may lead to an improvement in survival. In an attempt to address this problem, a number of studies have focused on administering chemotherapy in various carriers. 1, 2 Liposomes are among the most useful drug carriers, [3] [4] [5] [6] [7] and it has been shown that the therapeutic effects of anticancer drugs were increased when the drugs were encapsulated in liposomes, 8, 9 mainly because of a reduction in toxicity of the entrapped antineoplastic agents. 10 The effectiveness of liposomalization has been recognized because liver capillaries possess a discontinuous basement membrane and a fenestrated endothelial lining so that liposomes preferentially target the liver; 11 however, a rapid uptake of the liposomes by the reticuloendothelial system (RES) has been shown to decrease the efficacy of liposomalization. 8, 12, [13] [14] [15] To increase specific delivery to the liver without entrapment by the RES, various methods have been tried, including the administration of liposomal agents through the portal vein 16 or hepatic artery, 17 and the use of small-sized liposomes; 18 however, the antitumor effect decreased with these variations. It is well known that an asialoglycoprotein receptor exists on the surface of hepatocytes that specifically recognizes galactose moieties. 19, 20 Based on this finding, targeting the liver using liposomes modified with galactose has been reported. Asialofetuin, a glycoprotein-labeled liposome, was specifically incorporated into isolated hepatocytes through the action of a galactose-binding protein in vitro, 21 and lactosylceramide, a glycolipid-containing liposome, was entrapped by hepatocytes preferentially, as compared to control liposomes, after an intracardiac injection into rats. 22 These findings prompted us to study the antituAbstract Adriamycin (ADM) was encapsulated in a galactose-conjugated hepatotropic liposome (hLip-ADM) and its ability to enhance the antitumor effect while reducing toxicity was compared with that of free ADM and a control Lip-ADM (cLip-ADM), in two in vitro animal models. Liver metastases were induced in rats by an intravenous injection of 8 ϫ 10 6 AH-130 rat hepatoma tumor cells. All forms of the ADM completely inhibited liver metastasis when given at a dose of 5 mg/kg on day 14 after tumor implantation, whereas liver metastatic foci were observed in six of ten rats in the control group. The reduction in ADM toxicity by liposomalization was remarkable, as significant body weight loss was observed only in the free ADM group, in which four of ten rats died. Additional experiments utilized a human colon cancer xenograft (TK-4) to induce the growth of the liver metastases in mice by orthotopic implantation. The hLip-ADM completely inhibited liver metastasis in rats (0/11), whereas liver metastases developed in 10 of 12 mice in the control group and in 5 of 12 mice given cLip-ADM. Interestingly, liposomal ADM did not have a significant inhibitory effect on transplanted tumor growth assessed 6 weeks after transplantation. These findings indicate that hLip-ADM may be an effective strategy for inhibiting liver metastases from human colon cancer. mor effects of colorectal chemotherapy using liposomes modified with galactose.
In this paper, we examined in vitro whether a liposomal adriamycin (ADM) preparation modified with galactose could maintain an antitumor effect while reducing the toxicity of ADM similar to a conventional liposomal ADM preparation, against the rat AH-130 cell line. We then compared the therapeutic effect of the two ADM liposomal preparations in a nude mouse model of human colon metastatic liver tumors induced by orthotopic implantation into histologically intact tissue.
Materials and Methods

Chemicals
Dipalmitoylphosphatidylcholine (DPPC), dicetylphosphate (DCP), and cholesterol (CH) were purchased from Sigma Chemical (St. Louis, MO, USA). Phospholipid test kits were obtained from Wako Pure Chemical Industries (Osaka, Japan). Phosphate-buffered saline (PBS) was obtained from Nissui Pharmaceutical (Tokyo, Japan). The galactosyl ligands {8-(2-hexadecyloctadecanoylamido)-3,6-dioxaoctyl}--dgalactoside (Gal-t-psa) were prepared as previously described by Sasaki et al. 23 
Preparation of ADM-Entrapped Liposomes
Liposomes were prepared according to the method of Bangham and Horne 24 with some modifications. The control liposomes contained 250 mM DPPC, 250 mM CH, and 25 mM DCP. Galactosylated liposomes were constructed using 50 mM Gal-t-psa, together with DPPC, CH, and DCP, which were used as the control liposomes. These lipids were dissolved in 10 ml of 1 : 1 chloroform/methanol (v/v). The solvent was distilled in a stream of nitrogen with heating, followed by drying under reduced pressure. The residues were hydrated with 5 ml of 0.3 M citric acid solution (pH 3.8), vortexed mechanically, and sonicated for 10 min with a bath-type sonicator (Branson B1200, Emerson-Japan, Tokyo, Japan). The liposomes were extruded through polycarbonate membranes (Nuclepore, Boston, MA, USA) with successive pore sizes of 200 and 100 nm. These procedures were done at a temperature above the gelliquid crystalline phase transition temperature of the lipid materials. The pH of the liposomes were adjusted to 7.4, and 5 ml of ADM (15 mg/ml) was added. The liposome mixture was incubated for 10 min at 60°C. Nonencapsulated ADM was removed by gel filtration (Sephadex G50; Pharmacia, Uppsala, Sweden). The phospholipid concentration was measured by a phospholipid test kit. The size of the liposomes was determined using a submicron particle analyzer (NICOMP 370, Pacific Scientific, Baltimore, MD, USA). The mean diameter of the liposomes ranged from 120 to 150 nm. The liposome showed a multilamellar structure on negatively stained electron micrographs.
Animals
Male BALB/c-nu/nu mice were obtained from Clea Japan (Tokyo, Japan) and used at 5-6 weeks of age. Male Donryu rats (weight 100-120 g) were obtained from Nihon SLC (Shizuoka, Japan).
Liver Concentration of ADM
Mice were separated into three groups, given an intravenous tail vein injection of either free ADM (2 mg/kg), control liposomes containing ADM (cLip-ADM), or galactosylated liposomes containing ADM (hLip-ADM). At fixed times after the injection, the mice were killed and the liver concentration of ADM was determined by high-performance liquid chromatography (HPLC).
AH-130 Tumor Cells
The AH-130 rat hepatoma cell line was kindly supplied by Kyowa Hakko Kogyo (Tokyo, Japan) and introduced into rats by intraperitoneal inoculation at weekly intervals. The rats were anesthetized and a small midline incision was made to exteriorize the superior mesenteric vein (SMV). Viable AH-130 tumor cells (8 ϫ 10 6 /0.5 ml) were injected into the SMV with a 27-gauge needle. Liver metastases were found macroscopically, 10-14 days after injection. Using this metastatic model, it was possible to evaluate the antimetastatic effect of ADM over a short period of time.
Human Colon Cancer Xenograft
The well-differentiated human colon adenocarcinoma TK-4 xenograft was established in our department and used in this study. This xenograft was maintained by serial transplantation in nude mice. Small pieces of TK-4 were resected aseptically during the exponential growth phase. Mice were anesthetized and a small midline incision was made. The colocecal portion of the intestine was carefully exteriorized, and the serosa was removed at the site where the tumor pieces were to be implanted. A piece of tumor, 5 mm in diameter, was then fixed on each injured site of the serosal surface with 6-0 Dexon (Davis-Geck, Manati, Puerto Rico) transmural sutures. The intestine was returned to the abdominal cavity and the abdominal wall and skin were closed with 6-0 Dexon sutures. The animals were kept in a sterile environment. Liver metastases were identified 5 weeks after implantation (Fig. 1) .
Therapeutic Effect and Side Effects of ADM in Liposomes
Rats were divided randomly into four groups and treated with three tail-vein injections of either normal saline, free ADM (5 mg/kg), cLip-ADM, or hLip-ADM at 4-day intervals on days 5, 9, and 13 after inoculation. The mice were divided into three groups, each of which was given three injections of normal saline, cLip-ADM, or hLip-ADM at 4-day intervals on days 21, 25, and 29 after implantation. The rats were killed on day 14 and the mice were killed on day 35. The effect of treatment on the liver metastasis and the side effects were then evaluated. The actual tumor weight of the cecal wall after treatment was measured and the therapeutic effect on local tumor growth was also assessed in the mice.
Statistical Analysis
The Student's t-test and the 2 -test were used for statistical analysis. A P value of 0.05 or less was considered significant.
Results
Liver Concentration of ADM
The liver concentration of ADM was determined by HPLC 5 min, and 1, 6, or 24 h after the injection of free ADM, cLip-ADM, or hLip-ADM. The liver concentration in the mice given hLip-ADM was higher 1, 6, and 24 h after injection compared with the other two groups; however, significant differences were found only 1 h after injection (Fig. 2) .
Rat Liver Metastasis and Body Weight
Liver metastases were found in six of the ten (60%) rats in the control group, but there were no liver metastases in the other three groups given ADM (Table 1 ). In the free ADM group, body weight loss was remarkable and four of ten rats died, apparently from ADM toxicity. In contrast, there was no significant body weight loss in the other three groups. The actual body weights (mean Ϯ SD) were: control, 203.7 Ϯ 11.24 g; free ADM, 145.3 Ϯ 26.61 g; cLip-ADM, 204.3 Ϯ 13.28 g; hLip-ADM, 202.9 Ϯ 11.90 g (Fig. 3 ). Significant differences were found between the free ADM group and the other three groups (P Ͻ 0.001).
Mouse Liver Metastasis and Body Weight
The free ADM group was excluded from these experiments because of the severe side effects of ADM. Liver metastasis in the mice given TK-4 tumors after treatment were found in 10 of 12 mice in the control group, 5 of 12 mice in the cLip-ADM group, and 0 of 11 mice in the hLip-ADM group (Table 2 ). Significant differences were found between the hLip-ADM group and the controls (P Ͻ 0.001) and the mice treated with cLip-ADM (P Ͻ 0.05). Figure 4 shows the body weights of the mice implanted with TK-4 tumors after treatment. There were no significant differences among any of the groups. Figure 5 shows the weight of the local tumors implanted on the cecal wall after treatment. The tumor weights did not differ significantly, indicating that liposomal ADM did not have an inhibitory effect on tumor growth.
Discussion
Liposomes can effectively be used as drug carriers because they are nontoxic and biodegradable. Drugs can be entrapped in liposomes without any modification and they are protected from enzymatic attack or immune recognition until they reach the target cells. Based on recent advances in the field of solid tumor metastasis, various strategies have been developed utilizing liposomalization. Sharma et al. demonstrated that thermosensitive liposomes encapsulating Taxol in combination with hyperthermia could reduce tumor volume and increase survival time in a murine melanoma model, 25 and Khanna et al. showed that interleukin-2 liposome inhalation therapy was a nontoxic and effective treatment for dogs with osteosarcoma pulmonary metastases. 26 The liposomalization of antineoplastic agents has also been used by a number of investigators who have shown that the therapeutic effects of antineoplastic agents could be increased and prolonged, and that the side effects decreased when the drugs were encapsulated in liposomes. 1, 5, 8, 9, 27 Liposomal ADM has been used clinically and is available commercially. The entrapment ratio of ADM in liposomes is high compared with other antineoplastic agents because of its high affinity to lipids. Another advantage of liposomal ADM is its high affinity for the liver and the superior antitumor effect of ADM against metastatic liver cancer. 11 Lip-ADM has also been reported to have an excellent clinical therapeutic effect on metastatic liver tumors from gastrointestinal cancer. 28 Pisani et al. reported that approximately 400 000 people die of colorectal cancer in the world every year, 29 and liver metastases develop in approximately 60% of patients with colorectal cancer. Liver resection is currently the only treatment that offers long-term survival, following which the 5-year survival rates range from 25% to 40%; however, less than 20% of patients are candidates for resection. The prognosis for the remaining patients is poor, as palliative chemotherapy and symptomatic care are the only available options. 30 Therefore, the control of liver metastasis in patients with colorectal cancer is a critical problem. Since a remarkable improvement in prognosis could be expected if liver metastasis was inhibited, a number of studies have focused on this problems. Okamoto et al. demonstrated an inhibition of colon cancer liver metastasis in nude mice by the in vivo administration of antivascular endothelial growth factor antibody, 31 and Hasegawa et al. reported that Matrilysin, the smallest member of the matrix metalloproteinase family and a specific antisense oligonucleotide, inhibited human colon cancer liver metastasis. 32 Over the past 30 years, various forms of liposomalization-targeted chemotherapy to prevent metastatic disease from colon cancer have been investigated.
The liver is one of the few organs in the body where parenchymal cells are directly accessible from the blood compartment due to the lack of a continuous basement membrane and the presence of a fenestrated endothelial lining. 11 This makes hepatocytes an exceptionally suitable target for a drug delivery system such as liposomes; however, a considerable percentage of liposomes are very rapidly cleared from the circulation by the RES, especially Kupffer cells. In an attempt to increase the percentage of liposomes taken up by hepatocytes, Mayer et al. reported that variations in vesicle size strongly influenced the antitumor activity of liposomal adriamycin, and demonstrated that small-sized liposomes were more effective than larger ones. 18 Furthermore, Ghosh et al. reported that liposomes modified with galactose accumulated in the liver to a greater extent than control liposomes, and were targeted to the liver parenchymal cells, 33 as there is an asialoglycoprotein receptor on the surface of the hepatocytes that specifically recognizes galactose glycoproteins. 19, 20 Based on the findings of these studies, we adopted a small-sized liposome with a mean diameter of 120-150 nm, modified with galactose in this study. Many researchers have modified liposomes with galactose, especially in the structure or composition of the ligands that are specifically distributed to the liver, but no experimental research study examining the possible antitumor effects of liposomes modified with galactose has been reported.
In the present study, we injected massive numbers of tumor cells into the liver and metastatic foci had formed within 2 weeks after injection. A 5-mg dose of liposomal ADM was a sufficient to inhibit the formation of metastatic foci, but there was no difference between the type of liposomal preparation and the antimetastatic effect. On the other hand, a reduction in toxicity was clearly demonstrated. As liposomalization can target a drug directly to the tumor cells and away from sensitive tissues such as the heart and bone marrow, the toxicity associated with the use of free ADM is reduced. 34 Although no toxicity data was given in this study, we believe that the prolonged survival of the rats treated with liposomal ADM indicates a reduction in potentially lethal side effects such as cardiotoxicity or bone marrow suppression.
Unlike the rat model, the TK-4 mouse model was complicated and required an extended period of time to evaluate liposomalization in a simulated clinical situation. In this setting, there was a superior inhibitory effect of hLip-ADM on liver metastasis; however, the effect of cLip-ADM was not significantly different from that in the control group (Table 2) . To the best of our knowledge, this is the first report to document a therapeutic effect of hepatotropic liposomal ADM on human colorectal cancer liver metastases.
Interestingly, hLip-ADM did not inhibit the growth of transplanted tumors implanted on the cecal wall (Fig.  5) . Since free ADM did not inhibit the tumor growth of TK-4 transplanted subcutaneously (data not shown), there may be a decreased sensitivity of the TK-4 cells to ADM. This data suggests that hLip-ADM should not be used to shrink a primary tumor of colorectal cancer, but rather to prevent micrometastasis to the liver. In other words, there should be one strategy for the treatment of colorectal cancer, whereby primary lesions are treated surgically and liver metastases are controlled by hLip-ADM.
It is well known that liposomal ADM modified with galactose is recognized by the galactose receptor on the surface of the hepatocyte and incorporated into the hepatocyte by endocytosis, 18, 33, 35 but the existence of the galactose receptor on the surface of tumor cells has not been demonstrated to date. Furthermore, it is still unknown how liposomal ADM modified with galactose incorporated into a hepatocyte increases the concentration of ADM within the metastatic tumor. We presently assume that hLip-ADM incorporated into the hepatocyte increases the concentration of ADM within the whole liver, consequently demonstrating the antimetastatic effect. In this study, we were not able to measure the concentration of ADM in both normal liver tissue and metastatic foci, as metastasis was not observed in all of the treatment groups using the rat AH-130 model, and it was very difficult to separate the metastatic foci from normal liver tissue in the mouse experimental TK-4 model. However, as other authors have measured ADM concentrations in metastatic liver tumor cells and intratumoral distributions of liposomal ADM via fluorescence microscopy, 36,37 our future investigations are aimed at identifying ADM concentration quantification methods in our animal tumor models. Interestingly, no obvious damage to the hepatocytes by hLip-ADM was observed histologically (data not shown).
In conclusion, the findings of this study suggested that hLip-ADM may be able to prevent human colon cancer liver metastasis in xenografts without increasing the toxicity of ADM, and that hLip-ADM could be effective for preventing liver metastases from human colon cancer.
